Pancreatic Cancer Research

ResearcherMorristown Medical CenterActive in the last 2 years

Angela Tatiana Alistar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0009-0009-0473-7513; OpenAlex author ID A5023523894. Sources: ClinicalTrials.gov.

Their work

Papers
5 (first author 1, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2017: 1 paper, 1 trial · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 5

  1. A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancre… Co-author DOI 10.1002/cncr.70343↗
  2. Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. Co-author DOI 10.1093/oncolo/oyag023↗
  3. Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. First author DOI 10.1093/oncolo/oyae323↗
  4. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Tr… Co-author DOI 10.1158/1078-0432.ccr-21-0929↗
  5. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-cen… Co-author DOI 10.1016/s1470-2045(17)30314-5↗

Trials 1

  1. A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer Principal investigator NCT03435289↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Erkut Hasan Borazanci · 3 shared papers, 2021–2026 · strength 0.52
  2. Vincent M. Chung · 2 shared papers, 2025–2026 · strength 0.45
  3. Derek Cridebring · 2 shared papers, 2025–2026 · strength 0.42
  4. Gayle Jameson · 2 shared papers, 2025–2026 · strength 0.42
  5. Daniel D. Von Hoff · 2 shared papers, 2025–2026 · strength 0.42
  6. Mariano Ponz‐Sarvisé · 2 shared papers, 2021–2026 · strength 0.34
  7. Teresa Mercade Macarulla · 2 shared papers, 2021–2026 · strength 0.34
  8. Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.24
  9. Do‐Youn Oh · 1 shared paper, 2026 · strength 0.24
  10. Jens Thomas Siveke · 1 shared paper, 2026 · strength 0.24
  11. Ben George · 1 shared paper, 2026 · strength 0.24
  12. Jill Lacy · 1 shared paper, 2026 · strength 0.24
  13. Charles D. Lopez · 1 shared paper, 2026 · strength 0.24
  14. Gulam Abbas Manji · 1 shared paper, 2026 · strength 0.24
  15. Drew Warren Rasco · 1 shared paper, 2026 · strength 0.22
  16. Joshua D. Rabinowitz · 1 shared paper, 2026 · strength 0.22
  17. Richard C. Frank · 1 shared paper, 2026 · strength 0.22
  18. Diana L. Hanna · 1 shared paper, 2026 · strength 0.22
  19. Carlos Roberto Becerra · 1 shared paper, 2025 · strength 0.20
  20. Haiyong Han · 1 shared paper, 2025 · strength 0.20
  21. Anup Kasi · 1 shared paper, 2025 · strength 0.20
  22. Ronald M. Evans · 1 shared paper, 2025 · strength 0.20
  23. Michael T. Barrett · 1 shared paper, 2025 · strength 0.20
  24. Manuel M. Hidalgo · 1 shared paper, 2021 · strength 0.10
  25. Carmen Guillén‐Ponce · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.